We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Novartis, Merck and Pfizer
Read MoreHide Full Article
For Immediate Release
Chicago, IL – March 25, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novartis (NVS - Free Report) , Merck (MRK - Free Report) and Pfizer (PFE - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Pharma Stock Roundup: News on NVS, MRK and PFE
There were not many developments in the drugs sector this week. The FDA approved Novartis' Pluvicto for a certain type of advanced prostate cancer and Merck's Keytruda for a second indication in endometrial carcinoma. Pfizer announced positive top-line data from a late-stage ulcerative colitis study on pipeline candidate, etrasimod.
Recap of the Week's Most Important Stories
FDA Approves Novartis' Pluvicto for Advanced Prostate Cancer: The FDA approved Novartis' targeted radioligand therapy (RLT) Pluvicto for treating patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) These patients with progressing mCRPC were pre-treated with multiple lines of anti-cancer therapies and have limited treatment options.
The FDA also approved a complementary diagnostic imaging agent, Locametz for the identification of PSMA-positive lesions in adult patients with mCRPC. Pluvicto's approval was based on data from the pivotal phase III VISION study. Data from the study showed that pre-treated PSMA-positive mCRPC patients who were given Pluvicto plus standard of care experienced a statistically significant reduction in risk of death. Two other pivotal late-stage studies are ongoing on Pluvicto in earlier lines of treatment for metastatic prostate cancer.
FDA Approves Merck's Keytruda for 2nd Indication in Endometrial Cancer: The FDA approved Merck's Keytruda as a single agent for certain patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial carcinoma who have disease progression, following prior systemic therapy and are not candidates for curative surgery or radiation.
The approval was based on data from two cohorts of the KEYNOTE-158 study. This is the second indication for Keytruda in endometrial cancer. In endometrial carcinoma, Keytruda is already approved in combination with partner Eisai's Lenvima for treating endometrial carcinoma that is not MSI-H/dMMR in patients who have disease progression, following prior systemic therapy and are not candidates for curative surgery or radiation.
Pfizer's Etrasimod Meets Goal in Ulcerative Colitis Study: Pfizer's phase III study evaluating pipeline candidate, etrasimod for the treatment of moderately to severely active ulcerative colitis (UC) met primary and key secondary endpoints. Data from the ELEVATE 12 study showed that patients treated with etrasimod (2 mg once daily) achieved statistically significant improvements in the primary endpoint of clinical remission at week 12 as compared with placebo.
The secondary endpoints of the study were also met with statistical significance. The 354 UC patients enrolled in the study had previously failed or were intolerant to at least one conventional, biologic, or JAK therapy.
Another study, ELEVATE 52, is also ongoing on the candidate, data from which are expected to be announced by the end of the first quarter. Data from ELEVATE 12 and ELEVATE 52 studies are expected to form the basis of the regulatory submissions.
Pfizer is voluntarily recalling some lots of its hypertension medicine, Accuretic and its authorized versions due to the presence of a nitrosamine, N-nitroso-quinapril. Nitrosamines are impurities present in water and food items and people are exposed to them. However, if these impurities are present above acceptable levels and people are exposed to them over the long term, these may increase the risk of cancer.
The NYSE ARCA Pharmaceutical Index rose 1% in the last five trading sessions.
Watch out for regular pipeline and regulatory updates next week.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Novartis, Merck and Pfizer
For Immediate Release
Chicago, IL – March 25, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novartis (NVS - Free Report) , Merck (MRK - Free Report) and Pfizer (PFE - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Pharma Stock Roundup: News on NVS, MRK and PFE
There were not many developments in the drugs sector this week. The FDA approved Novartis' Pluvicto for a certain type of advanced prostate cancer and Merck's Keytruda for a second indication in endometrial carcinoma. Pfizer announced positive top-line data from a late-stage ulcerative colitis study on pipeline candidate, etrasimod.
Recap of the Week's Most Important Stories
FDA Approves Novartis' Pluvicto for Advanced Prostate Cancer: The FDA approved Novartis' targeted radioligand therapy (RLT) Pluvicto for treating patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) These patients with progressing mCRPC were pre-treated with multiple lines of anti-cancer therapies and have limited treatment options.
The FDA also approved a complementary diagnostic imaging agent, Locametz for the identification of PSMA-positive lesions in adult patients with mCRPC. Pluvicto's approval was based on data from the pivotal phase III VISION study. Data from the study showed that pre-treated PSMA-positive mCRPC patients who were given Pluvicto plus standard of care experienced a statistically significant reduction in risk of death. Two other pivotal late-stage studies are ongoing on Pluvicto in earlier lines of treatment for metastatic prostate cancer.
FDA Approves Merck's Keytruda for 2nd Indication in Endometrial Cancer: The FDA approved Merck's Keytruda as a single agent for certain patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial carcinoma who have disease progression, following prior systemic therapy and are not candidates for curative surgery or radiation.
The approval was based on data from two cohorts of the KEYNOTE-158 study. This is the second indication for Keytruda in endometrial cancer. In endometrial carcinoma, Keytruda is already approved in combination with partner Eisai's Lenvima for treating endometrial carcinoma that is not MSI-H/dMMR in patients who have disease progression, following prior systemic therapy and are not candidates for curative surgery or radiation.
Pfizer's Etrasimod Meets Goal in Ulcerative Colitis Study: Pfizer's phase III study evaluating pipeline candidate, etrasimod for the treatment of moderately to severely active ulcerative colitis (UC) met primary and key secondary endpoints. Data from the ELEVATE 12 study showed that patients treated with etrasimod (2 mg once daily) achieved statistically significant improvements in the primary endpoint of clinical remission at week 12 as compared with placebo.
The secondary endpoints of the study were also met with statistical significance. The 354 UC patients enrolled in the study had previously failed or were intolerant to at least one conventional, biologic, or JAK therapy.
Another study, ELEVATE 52, is also ongoing on the candidate, data from which are expected to be announced by the end of the first quarter. Data from ELEVATE 12 and ELEVATE 52 studies are expected to form the basis of the regulatory submissions.
Pfizer is voluntarily recalling some lots of its hypertension medicine, Accuretic and its authorized versions due to the presence of a nitrosamine, N-nitroso-quinapril. Nitrosamines are impurities present in water and food items and people are exposed to them. However, if these impurities are present above acceptable levels and people are exposed to them over the long term, these may increase the risk of cancer.
The NYSE ARCA Pharmaceutical Index rose 1% in the last five trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
In the last five trading sessions, Roche rose the most (3.8%) while Pfizer declined the most (1.4%).
In the past six months, AbbVie has recorded the maximum gain (50.4%) while Novartis recorded the least gain (6.4%).
(See the last pharma stock roundup here: PFE, SNY, ABBV's Pipeline Updates, BAYRY's Unit Sale)
What's Next in the Pharma World?
Watch out for regular pipeline and regulatory updates next week.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.